Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Help North Carolina rebuild: WRAL's Hurricane Helene recovery fund raises $900K+
Recommended
NC elections upended by Helene: Voting could be delayed, ballots might be lost. Here's what you need to know
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
11.90
+0.03 (+0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,523,165
Open
11.92
Bid (Size)
11.77 (1)
Ask (Size)
11.98 (4)
Prev. Close
11.87
Today's Range
11.80 - 12.01
52wk Range
8.245 - 13.05
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's After-Market Session
October 03, 2024
Via
Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
October 03, 2024
On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade.
Via
Benzinga
Performance
YTD
+4.85%
+4.85%
1 Month
-1.82%
-1.82%
3 Month
+3.48%
+3.48%
6 Month
+9.78%
+9.78%
1 Year
+18.06%
+18.06%
More News
Read More
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
September 18, 2024
Via
Benzinga
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
From
Roivant Sciences
Via
GlobeNewswire
4 Analysts Assess Roivant Sciences: What You Need To Know
September 11, 2024
Via
Benzinga
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
June 18, 2024
Via
Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
May 31, 2024
Via
Benzinga
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
April 22, 2024
Via
Benzinga
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
September 10, 2024
Via
Benzinga
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
September 10, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
September 10, 2024
From
Roivant Sciences
Via
GlobeNewswire
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
September 09, 2024
Via
Benzinga
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024
From
Roivant Sciences
Via
GlobeNewswire
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
August 29, 2024
Via
Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
August 08, 2024
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
July 25, 2024
From
Roivant Sciences
Via
GlobeNewswire
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
May 30, 2024
Via
InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
May 30, 2024
From
Roivant Sciences
Via
GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
May 22, 2024
Via
Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
May 16, 2024
From
Roivant Sciences
Via
GlobeNewswire
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Via
InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
May 01, 2024
Via
InvestorPlace
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
April 02, 2024
Via
Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
April 02, 2024
Via
Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
April 02, 2024
From
Roivant Sciences
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.